GSK builds oncology pipeline as drug shown to help myeloma patients
GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
With New CEO MIA, Gilead Reports Tough Q4 and 2018
Gilead Sciences reported earnings per share profits for the 2018 fourth quarter of $1.44 per share, below analysts’ expectations of $1.70. Revenue for the quarter was $5.8 billion, better than Wall Street’s $5.5 billion expectations, but down from $5.949 billion in the same quarter during 2017.
Celgene Revamps Pact With Sutro Biopharma
Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!